Anzeige
Mehr »
Login
Donnerstag, 05.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 09.04.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Purmo Group Oyj: Resolutions of Purmo Group Plc's Annual General Meeting181Purmo Group Plc | Stock Exchange Release | April 09, 2024 at 15:45:00 EEST Purmo Group Plc's Annual General Meeting was held today, Tuesday 9 April 2024 in Helsinki.The Annual General Meeting approved...
► Artikel lesen
09.04.Mondelez International, Inc.: Mondelez International's Near-term 2030 Targets and 2050 Net-Zero Targets Validated by Science Based Targets Initiative855Approval reinforces Mondelez International's commitment to its mission to create a more sustainable snacking company CHICAGO, April 09, 2024 (GLOBE NEWSWIRE) -- Mondelez International, Inc. (Nasdaq:...
► Artikel lesen
09.04.DGB Group N.V.: DGB Group achieves project milestone and receives €150,000 upfront payment180DGB Group N.V. ("DGB", "the Group", or "the Company") (Euronext: DGB: NL000916951), a leading carbon project developer and ecosystem restoration company, successfully manufactured and distributed its...
► Artikel lesen
09.04.Kaixin Auto Holdings Announces Name Change201HANGZHOU, China, April 09, 2024 (GLOBE NEWSWIRE) -- Kaixin Auto Holdings ("Kaixin" or the "Company") (NASDAQ: KXIN) today announced that it has changed its legal name from Kaixin Auto Holdings to...
► Artikel lesen
09.04.Halcones Precious Metals Inc.: Halcones Withdraws from Option to Acquire the Carachapampa Project in Chile112TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Halcones Precious Metals Corp. (TSX - V: HPM) (the "Company" or "Halcones") has withdrawn from its option to acquire the Carachapampa project (the "Project")...
► Artikel lesen
09.04.ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL")142- Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide ("R2")- Evorpacept plus R2 was well tolerated with a safety profile...
► Artikel lesen
09.04.Movella Holdings, Inc.: Movella Announces Listing on OTC Pink Market387HENDERSON, Nev., April 09, 2024 (GLOBE NEWSWIRE) -- Movella Holdings Inc. (NASDAQ: MVLA) ("Movella" or the "Company"), a leading full-stack provider of sensors, software, and analytics that enable...
► Artikel lesen
09.04.Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024320Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid...
► Artikel lesen
09.04.Prelude Therapeutics, Inc.: Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting96Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
► Artikel lesen
09.04.Jianzhi Education Technology Group Company Limited Reports Fiscal Year 2023 Financial Results217BEIJING, April 09, 2024 (GLOBE NEWSWIRE) -- Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ: JZ), a leading provider of digital educational content in China...
► Artikel lesen
09.04.Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs125First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for...
► Artikel lesen
09.04.IN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024188- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology...
► Artikel lesen
09.04.Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to May 9, 202454New York, NY, April 09, 2024 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (Nasdaq: GLLI, GLLIW, GLLIR, GLLIU) ("Globalink" or the "Company"), a special purpose acquisition company, announced today...
► Artikel lesen
09.04.O-I Glass, Inc.: O-I Glass Drinktainer Enters RTD Market395Right Coast Spirits Italian Ice to be first brand packed in DrinktainerTM via O-I and FX Matt contract packing collaboration Release pairs the sleek, modern design of Drinktainer with refreshing...
► Artikel lesen
09.04.Intrepid Potash, Inc: Intrepid Announces Accident Involving CEO203Denver, CO, April 09, 2024 (GLOBE NEWSWIRE) -- Intrepid Potash, Inc. ("Intrepid", "we," or "our") (NYSE:IPI) today announced that on Saturday, April 6, 2024, Bob Jornayvaz was involved in an accident...
► Artikel lesen
09.04.Nasdaq, Inc.: Nasdaq Announces End of Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 28, 2024152NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- At the end of the settlement date of March 28, 2024, short interest in 3,102 Nasdaq Global MarketSM securities totaled 11,297,406,980 shares compared with...
► Artikel lesen
09.04.ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024179PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically...
► Artikel lesen
09.04.Rakovina Therapeutics Inc: Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today107VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), ("Rakovina" or the "Company"), a biopharmaceutical company dedicated to improving the lives...
► Artikel lesen
09.04.NeurAxis, Inc.: NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results171CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
► Artikel lesen
09.04.Shattuck Labs, Inc.: Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024108- Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance...
► Artikel lesen
Seite:  Weiter >>